Q BioMed Launches New Website Strontium89.com and Digital Marketing Campaign
NEW YORK, May 15, 2020 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announces the launch of its marketing campaign for its FDA approved non-opioid metastatic bone pain drug Strontium89 (Strontium Chloride Sr-89 Injection, USP). A product website for U.S. healthcare professionals and consumers has been launched at Strontium89.com to support Q BioMed’s full scale digital marketing program reaching both healthcare professionals and patients.
In the Strontium89 pivotal trial, as many as 79% of patients had pain relief with Strontium89, and twice as many patients treated with Strontium89 had no pain for 3 months compared with placebo. Further, new pain sites were less frequent in patients treated with Strontium89,. Strontium89 is administered once every 3 months via injection, and patients can be re-treated if needed. With an estimated 10 million people living with bone metastases, Q BioMed anticipates broad market re-acceptance for this well-established, non-opioid option for bone pain management. Please see Important Safety Information below.
Q BioMed’s marketing campaign is focused on driving awareness of Strontium89 availability, product benefits and safety profile, appropriate patient populations, and on providing support for ordering and administering treatment. The initial digital marketing campaign is designed for maximum impact by reaching physicians without in-person sales representative interactions during the current social distancing and other extraordinary circumstances due to COVID-19. Q BioMed is also deploying a direct-to-patient campaign, outreach to patient advocacy groups, and intends to roll-out an in-person sales force to complement the institutional sales outreach conducted by its distributor, Jubilant Radiopharma™. Under this distribution relationship, Q BioMed has the ability to serve patients in all 50 states; Strontium89 has a favorable reimbursement status with Medicare, Medicaid and most private insurance companies.
“Q BioMed continues to ramp up commercial activities for our newly launched Strontium89. We are highly encouraged by the keen interest and engagement that we have already seen from healthcare providers. Several institutions are considering the use of Strontium89. We are confident that as our outreach grows, we’ll see increasing use of Strontium89 for patients who can benefit from non-opioid pain relief for bone cancer metastases,” stated Q BioMed CEO Denis Corin.
Q BioMed plans to launch the drug in global markets, including Europe, in the coming quarters.
Learn more at www.Strontium89.com.
INDICATIONS AND IMPORTANT SAFETY INFORMATION:
INDICATIONS AND USAGE
Strontium Chloride Sr-89 Injection, USP is indicated for the relief of bone pain in patients with painful skeletal metastases. The presence of bone metastases should be confirmed prior to therapy.
Read the full press here